{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:56:46Z","timestamp":1782449806855,"version":"3.54.5"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007480","name":"Universidad de Castilla-La Mancha","doi-asserted-by":"publisher","award":["2022-PROD-20657"],"award-info":[{"award-number":["2022-PROD-20657"]}],"id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science Innovation and Universities","doi-asserted-by":"publisher","award":["FPU21\/06866"],"award-info":[{"award-number":["FPU21\/06866"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejphar.2024.176702","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T05:30:39Z","timestamp":1717133439000},"page":"176702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"976","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-7561","authenticated-orcid":false,"given":"Jaime","family":"Fern\u00e1ndez-Bravo-Rodrigo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0430","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Cavero-Redondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-1065","authenticated-orcid":false,"given":"Maribel","family":"Lucer\u00f3n-Lucas-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-6953","authenticated-orcid":false,"given":"Irene","family":"Mart\u00ednez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Flor-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Barreda-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-8752","authenticated-orcid":false,"given":"Carlos","family":"Pascual-Morena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.176702_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.105900","article-title":"Monoclonal antibodies as a preventive therapy for migraine: a meta-analysis","volume":"195","author":"Alasad","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejphar.2024.176702_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12883-022-02710-5","article-title":"Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE","volume":"22","author":"Alsaadi","year":"2022","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s10194-022-01507-8","article-title":"Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis","volume":"23","author":"Andreou","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15360288.2020.1829249","article-title":"Erenumab and OnabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis","volume":"35","author":"Armanious","year":"2021","journal-title":"J. Pain Palliat. Care Pharmacother."},{"key":"10.1016\/j.ejphar.2024.176702_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2753.2010.01516.x","article-title":"Assessment of study quality for systematic reviews: a comparison of the Cochrane collaboration risk of bias tool and the effective public health practice project quality assessment tool: methodological research","volume":"18","author":"Armijo-Olivo","year":"2012","journal-title":"J. Eval. Clin. Pract."},{"key":"10.1016\/j.ejphar.2024.176702_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.2260","article-title":"Predictors of response to erenumab after 12 months of treatment","volume":"11","author":"Baraldi","year":"2021","journal-title":"Brain Behav"},{"key":"10.1016\/j.ejphar.2024.176702_bib7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/head.14194","article-title":"Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study","volume":"61","author":"Barbanti","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/head.14032","article-title":"Erenumab in the prevention of high-frequency episodic and chronic migraine: erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study","volume":"61","author":"Barbanti","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib9","first-page":"282","article-title":"[Pain catastrophizing and medication overuse in patients with chronic migraine]","volume":"70","author":"Barral","year":"2020","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/head.12550","article-title":"Acute migraine treatment in adults","volume":"55","author":"Becker","year":"2015","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/head.14291","article-title":"A real-world, observational study of erenumab for migraine prevention in Canadian patients","volume":"62","author":"Becker","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000527674","article-title":"Migraine disability and severity improvement during long-term treatment with erenumab","volume":"86","author":"Bolchini","year":"2023","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: epidemiology, burden, and comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.ejphar.2024.176702_bib14","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1007\/s10072-021-05105-5","article-title":"Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study","volume":"42","author":"Cainazzo","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2024.176702_bib15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/10600280221118402","article-title":"Efficacy and safety of erenumab, galcanezumab, and fremanezumab in the treatment of drug-resistant chronic migraine: experience in real clinical practice","volume":"57","author":"Cantarelli","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2024.176702_bib16","first-page":"8","article-title":"[Clinical experience with erenumab during the first year of treatment]","volume":"74","author":"Caso-Gonz\u00e1lez","year":"2022","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.medcli.2022.09.023","article-title":"Effectiveness of anti-CGRP monoclonal antibodies in the preventive treatment of migraine: a prospective study of 63 patients","volume":"160","author":"Castrillo","year":"2023","journal-title":"Med. Clin."},{"key":"10.1016\/j.ejphar.2024.176702_bib18","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1007\/s10072-022-06190-w","article-title":"Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study","volume":"43","author":"Cetta","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2024.176702_bib19","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1111\/head.13968","article-title":"Erenumab in chronic migraine: an Australian experience","volume":"60","author":"Cheng","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-022-01433-9","article-title":"Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study","volume":"23","author":"Cullum","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib21","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s10194-022-01480-2","article-title":"Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial","volume":"23","author":"De Icco","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib22","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1111\/ene.15075","article-title":"Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: a real-life study","volume":"28","author":"de Vries Lentsch","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr. Clin. Trials"},{"key":"10.1016\/j.ejphar.2024.176702_bib24","article-title":"Treatment of migraine attacks and prevention of migraine: guidelines by the German Migraine and","volume":"3","author":"Diener","year":"2019","journal-title":"Headache Society and the German Society of Neurology. Clinical and Translational Neuroscience"},{"key":"10.1016\/j.ejphar.2024.176702_bib25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejphar.2024.176702_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies - successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib27","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jpain.2013.03.010","article-title":"Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system","volume":"14","author":"Eftekhari","year":"2013","journal-title":"J. Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib28","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejphar.2024.176702_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40261-021-01059-w","article-title":"Real-life response to erenumab in a therapy-resistant case series of migraine patients from the province of qu\u00e9bec, eastern Canada","volume":"41","author":"Eghtesadi","year":"2021","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejphar.2024.176702_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph19031753","article-title":"The safety and efficacy of calcitonin gene-related peptide (CGRP) monoclonal antibodies for the preventive treatment of migraine: a protocol for multiple-treatment systematic review and meta-analysis","volume":"19","author":"Fern\u00e1ndez-Bravo-Rodrigo","year":"2022","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.ejphar.2024.176702_bib31","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s40261-023-01301-7","article-title":"Effectiveness of calcitonin gene-related peptide monoclonal antibodies in the prevention of migraine: a systematic review and meta-analysis of observational cohort studies","volume":"43","author":"Ferreira","year":"2023","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejphar.2024.176702_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s10194-022-01515-8","article-title":"Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results","volume":"23","author":"Gantenbein","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib33","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","article-title":"One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study","volume":"95","author":"Goadsby","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2024.176702_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s13760-023-02190-5","article-title":"Monoclonal anti-CGRP antibodies in post-menopausal women: a real-life study","volume":"123","author":"Guerzoni","year":"2023","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.ejphar.2024.176702_bib35","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1007\/s10072-022-05870-x","article-title":"Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data","volume":"43","author":"Guerzoni","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2024.176702_bib36","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/head.14423","article-title":"Different dosage regimens of erenumab for the treatment of migraine: a systematic review and meta-analysis of the efficacy and safety of randomized controlled trials","volume":"62","author":"Gui","year":"2022","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-020-01097-3","article-title":"Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies","volume":"21","author":"Haanes","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib38","series-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series, Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series","author":"Higgins","year":"2008"},{"key":"10.1016\/j.ejphar.2024.176702_bib39","article-title":"Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide's motor-stimulating and prosecretory function in the intestine","volume":"12","author":"Holzer","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejphar.2024.176702_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ejphar.2024.176702_bib41","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11916-018-0686-4","article-title":"CGRP monoclonal antibodies for the preventative treatment of migraine","volume":"22","author":"Israel","year":"2018","journal-title":"Curr. Pain Headache Rep."},{"key":"10.1016\/j.ejphar.2024.176702_bib42","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/papr.13196","article-title":"Dual therapy with Erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: a retrospective cohort study","volume":"23","author":"Jaimes","year":"2023","journal-title":"Pain Pract."},{"key":"10.1016\/j.ejphar.2024.176702_bib43","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1468-2982.2007.01303.x","article-title":"The triggers or precipitants of the acute migraine attack","volume":"27","author":"Kelman","year":"2007","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejphar.2024.176702_bib44","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/ene.15364","article-title":"Erenumab in chronic migraine: experience from a UK tertiary centre and comparison with other real-world evidence","volume":"29","author":"Khalil","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1129439","article-title":"Monoclonal antibodies for chronic migraine and medication overuse headache: a real-world study","volume":"14","author":"Krymchantowski","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","article-title":"A prospective real-world analysis of erenumab in refractory chronic migraine","volume":"21","author":"Lambru","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib47","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-019-01069-1","article-title":"Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety","volume":"79","author":"Lattanzi","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2024.176702_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","article-title":"A narrative review on the burden of migraine: when the burden is the impact on people's life","volume":"20","author":"Leonardi","year":"2019","journal-title":"J. Headache Pain"},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2024.176702_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/head.12505_2","article-title":"Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention","volume":"55","author":"Lipton","year":"2015","journal-title":"Headache"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2024.176702_bib50","first-page":"S33","article-title":"General principles of migraine management: the changing role of prevention","volume":"45","author":"Loder","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s10194-022-01456-2","article-title":"Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation","volume":"23","author":"Lowe","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2022.107169","article-title":"Effectiveness and safety of erenumab in chronic migraine: a Croatian real-world experience","volume":"214","author":"Mahovi\u0107","year":"2022","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejphar.2024.176702_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194425","article-title":"Real-life analysis with erenumab: first target therapy in the episodic and chronic migraine's prophylaxis","volume":"10","author":"Maraia","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2024.176702_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.117505","article-title":"Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): a network meta-analysis of randomized controlled trials","volume":"427","author":"Masoud","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2024.176702_bib55","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10072-020-04667-0","article-title":"Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna Headache Center","volume":"41","author":"Matteo","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2024.176702_bib56","article-title":"Real-world evidence for the safety and efficacy of CGRP monoclonal antibody therapy added to OnabotulinumtoxinA treatment for migraine prevention in adult patients with chronic migraine","volume":"12","author":"Mechtler","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejphar.2024.176702_bib58","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","article-title":"Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients","volume":"24","author":"Mu\u00f1oz-Vendrell","year":"2023","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrneurol.2017.151","article-title":"Migrainomics - identifying brain and genetic markers of migraine","volume":"13","author":"Nyholt","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib60","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s10194-020-01102-9","article-title":"Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy","volume":"21","author":"Ornello","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1154420","article-title":"Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study","volume":"14","author":"Overeem","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib62","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","article-title":"Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache","volume":"43","author":"Pensato","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2024.176702_bib63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s10072-020-04658-1","article-title":"Erenumab efficacy in highly resistant chronic migraine: a real-life study","volume":"41","author":"Pensato","year":"2020","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ejphar.2024.176702_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12103585","article-title":"Erenumab and possible CGRP effect on chronotype in chronic migraine: a real-life study of 12 Months treatment","volume":"12","author":"Pilati","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2024.176702_bib65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fneur.2020.00417","article-title":"Erenumab in chronic migraine patients who previously failed five first-line oral prophylactics and OnabotulinumtoxinA: a dual-center retrospective observational study","volume":"11","author":"Raffaelli","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib66","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2024.176702_bib67","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/head.13951","article-title":"Real-world patient experience with erenumab for the preventive treatment of migraine","volume":"60","author":"Robblee","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience","volume":"21","author":"Russo","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib69","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/head.14528","article-title":"A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine","volume":"63","author":"Sacc\u00e0","year":"2023","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib70","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s10194-018-0955-y","article-title":"European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention","volume":"20","author":"Sacco","year":"2019","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib72","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jsps.2022.06.015","article-title":"Assessment and characteristics of Erenumab therapy on migraine management","volume":"30","author":"Saeed","year":"2022","journal-title":"Saudi Pharmaceut. J."},{"key":"10.1016\/j.ejphar.2024.176702_bib73","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1111\/head.13652","article-title":"A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults","volume":"59","author":"Sakai","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.ejphar.2024.176702_bib74","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-020-01151-0","article-title":"Erenumab in highly therapy-refractory migraine patients: first German real-world evidence","volume":"21","author":"Scheffler","year":"2020","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib75","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10072-020-04670-5","article-title":"Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study","volume":"41","author":"Schiano di Cola","year":"2020","journal-title":"Neurol. Sci. : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology"},{"key":"10.1016\/j.ejphar.2024.176702_bib76","doi-asserted-by":"crossref","first-page":"e834","DOI":"10.1212\/CPJ.0000000000001112","article-title":"Erenumab discontinuation after 12-month treatment: a multicentric, observational real-life study","volume":"11","author":"Schiano di Cola","year":"2021","journal-title":"Neurology. Clinical practice"},{"key":"10.1016\/j.ejphar.2024.176702_bib77","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/ene.15761","article-title":"An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor","volume":"30","author":"Schiano di Cola","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.805334","article-title":"Erenumab for migraine prevention in a 1-year compassionate use program: efficacy, tolerability, and differences between clinical phenotypes","volume":"12","author":"Schoenen","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib79","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.115.227793","article-title":"Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor","volume":"356","author":"Shi","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176702_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.656294","article-title":"Additive interaction between onabotulinumtoxin-A and erenumab in patients with refractory migraine","volume":"12","author":"Silvestro","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib81","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s13760-021-01770-7","article-title":"Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice","volume":"122","author":"Storch","year":"2022","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.ejphar.2024.176702_bib82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s10194-021-01344-1","article-title":"Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany","volume":"22","author":"Straube","year":"2021","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib83","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2024.176702_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231177649","article-title":"Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan","volume":"43","author":"Suzuki","year":"2023","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ejphar.2024.176702_bib85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J. Headache Pain"},{"key":"10.1016\/j.ejphar.2024.176702_bib86","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","article-title":"Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Tepper","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib87","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1524-475X.2004.04006.x","article-title":"A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions","volume":"1","author":"Thomas","year":"2004","journal-title":"Worldviews Evidence-Based Nurs."},{"key":"10.1016\/j.ejphar.2024.176702_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.687697","article-title":"Assessment of the effect of erenumab on efficacy and quality-of-life parameters in a cohort of migraine patients with treatment failure in Cyprus","volume":"12","author":"Tziakouri","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176702_bib89","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/jcpt.13620","article-title":"Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: a retrospective cohort study","volume":"47","author":"Viudez-Mart\u00ednez","year":"2022","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.ejphar.2024.176702_bib90","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40120-018-0113-0","article-title":"Burden of migraine in europe using self-reported digital diary data from the migraine Buddy\u00a9 application","volume":"7","author":"Vo","year":"2018","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ejphar.2024.176702_bib91","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000018483","article-title":"Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials","volume":"98","author":"Zhu","year":"2019","journal-title":"Medicine"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992400390X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992400390X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T03:09:14Z","timestamp":1719630554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992400390X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":91,"alternative-id":["S001429992400390X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176702","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"176702"}}